Literature DB >> 26071363

Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute intermittent porphyria.

Chadi Homedan1, Caroline Schmitt2, Jihane Laafi3, Naïg Gueguen4, Valérie Desquiret-Dumas4, Hugo Lenglet5, Zoubida Karim5, Laurent Gouya2, Jean-Charles Deybach2, Gilles Simard1, Hervé Puy2, Yves Malthièry1, Pascal Reynier6.   

Abstract

Acute intermittent porphyria (AIP), an autosomal dominant metabolic disease (MIM #176000), is due to a deficiency of hydroxymethylbilane synthase (HMBS), which catalyzes the third step of the heme biosynthetic pathway. The clinical expression of the disease is mainly neurological, involving the autonomous, central and peripheral nervous systems. We explored mitochondrial oxidative phosphorylation (OXPHOS) in the brain and skeletal muscle of the Hmbs(-/-) mouse model first in the basal state (BS), and then after induction of the disease with phenobarbital and treatment with heme arginate (HA). The modification of the respiratory parameters, determined in mice in the BS, reflected a spontaneous metabolic energetic adaptation to HMBS deficiency. Phenobarbital induced a sharp alteration of the oxidative metabolism with a significant decrease of ATP production in skeletal muscle that was restored by treatment with HA. This OXPHOS defect was due to deficiencies in complexes I and II in the skeletal muscle whereas all four respiratory chain complexes were affected in the brain. To date, the pathogenesis of AIP has been mainly attributed to the neurotoxicity of aminolevulinic acid and heme deficiency. Our results show that mitochondrial energetic failure also plays an important role in the expression of the disease.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26071363     DOI: 10.1093/hmg/ddv222

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  15 in total

1.  Effect of 5-aminolevulinic acid on the expression of carcinogenesis-related proteins in cultured primary hepatocytes.

Authors:  P R Menezes; C B González; A O DeSouza; D A Maria; J Onuki
Journal:  Mol Biol Rep       Date:  2018-09-14       Impact factor: 2.316

2.  Pilot study of mitochondrial bioenergetics in subjects with acute porphyrias.

Authors:  Natalia Dixon; Ting Li; Brandon Marion; Denise Faust; Stephen Dozier; Anthony Molina; Sean Rudnick; Herbert L Bonkovsky
Journal:  Mol Genet Metab       Date:  2019-05-20       Impact factor: 4.797

Review 3.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

4.  Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Chunli Yu; Jinglan Zhang; Miguel A Gama-Sosa; Daniela D Pollak; Stefanie Berger; John D Phillips; Winfried Edelmann; Robert J Desnick
Journal:  Hum Mol Genet       Date:  2019-06-01       Impact factor: 6.150

5.  Complex response to physiological and drug-induced hepatic heme demand in monoallelic ALAS1 mice.

Authors:  Viktoria Vagany; Susan Robinson; Tatyana Chernova; Andrew G Smith
Journal:  Mol Genet Metab Rep       Date:  2021-11-12

6.  Selection and Validation of Reference Genes for RT-PCR Expression Analysis of Candidate Genes Involved in Morphine-Induced Conditioned Place Preference Mice.

Authors:  Qian Zhang; Mengting Zhang; Jiaqi Li; Hai Xiao; Dong Wu; Qiannan Guo; Yuwei Zhang; Hongdan Wang; Shengbin Li; Shixiu Liao
Journal:  J Mol Neurosci       Date:  2018-11-01       Impact factor: 3.444

7.  A mouse model of hereditary coproporphyria identified in an ENU mutagenesis screen.

Authors:  Ashlee J Conway; Fiona C Brown; Robert O Fullinfaw; Benjamin T Kile; Stephen M Jane; David J Curtis
Journal:  Dis Model Mech       Date:  2017-06-09       Impact factor: 5.758

8.  Feasibility of cellular bioenergetics as a biomarker in porphyria patients.

Authors:  Balu Chacko; Matilda Lillian Culp; Joseph Bloomer; John Phillips; Yong-Fang Kuo; Victor Darley-Usmar; Ashwani K Singal
Journal:  Mol Genet Metab Rep       Date:  2019-01-29

9.  A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.

Authors:  Helene J Bustad; Karen Toska; Caroline Schmitt; Marta Vorland; Lars Skjærven; Juha P Kallio; Sylvie Simonin; Philippe Letteron; Jarl Underhaug; Sverre Sandberg; Aurora Martinez
Journal:  Mol Ther       Date:  2019-12-04       Impact factor: 11.454

10.  Severe hydroxymethylbilane synthase deficiency causes depression-like behavior and mitochondrial dysfunction in a mouse model of homozygous dominant acute intermittent porphyria.

Authors:  Stefanie Berger; Miranda Stattmann; Ana Cicvaric; Francisco J Monje; Pierluca Coiro; Matej Hotka; Gerda Ricken; Johannes Hainfellner; Susanne Greber-Platzer; Makiko Yasuda; Robert J Desnick; Daniela D Pollak
Journal:  Acta Neuropathol Commun       Date:  2020-03-20       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.